Risk Factors Update Summary

• The Company increased the number of shares available under the 2018 Plan by 1,030,000 to a total of 1,970,000.
• The company is evaluating the impact of ASU F-14 on income tax disclosures within the financial statements.
• The company expects operating losses to continue, with profitability dependent on approvals and commercialization success.
• The company might not continue as a going concern due to substantial doubt about funding. This could lead to significant stockholder losses.
• Going concern uncertainty highlighted with net loss of $19.5 million in 2023, up from $19.0 million in 2022.
• The company's lead clinical program for advanced ovarian cancer is now in Phase 2 development.
• The Audit Committee operates under a written charter effective January 24, 2023.
• The Company sold 1,653,392 shares of stock in 2023, generating net proceeds of $2,465,781.
• Restricted cash decreased from $6.0 million to $3.0 million in 2023.
• Lessee's undiscounted obligation for lease payment increased from the fourth to the third fiscal year.
• The company sold $1.3 million of New Jersey NOLs in 2023, compared to $1.6 million in 2022.
• Cumulative net losses increased from approximately $369 million to $388 million, impacting financial stability.
• The Company repaid the outstanding principal balance, an early termination fee, and end-of-term charges in full satisfaction of the SVB Loan Facility on April 21, 2023.
• Net loss decreased from $35,898,234 in 2022 to $19,514,977 in 2023.
• Stock options granted increased from 432,500 to 1,063,482, a significant rise.
• Share-based payment awards outstanding decreased from 69,650 to 1,481 shares.
• Common stock shares issued decreased from 9,399,811 to 7,436,219, a significant drop.
• Topic 320 - SubTopic 10 was added with Section 50 - Paragraph 5C. This is a significant addition.
• Investment in debt securities - available for sale increased from $9,857,087 to $21,254,485.
• The company continues to trade on Nasdaq under the ticker symbol "IMNN." This change is significant for investors.
• Cumulative net losses increased to approximately $388 million in 2023 from $369 million in 2022.
• The 2021 Registration Statement limits offerings to one-third of public float, increasing flexibility.
• Additional paid-in capital increased by $93 million to $998 million.
• Net loss increased from $19,514,977 in 2022 to $35,898,234 in 2023.
• Share-based compensation unrecognized cost decreased from $3.8 million in 2022 to $2.7 million in 2023.
• The Company renewed its Huntsville facility lease for 11,420 square feet with monthly rent payments increasing from approximately $28,550 to $30,903.
• Inclusion of detailed financial data for property, plant, and equipment, with values for machinery and equipment.
• Net loss increased from $19.5 million to $19.0 million in 2023, with cumulative net losses rising to $388 million.
• Increase in deferred tax assets from $1,567,026 to $1,280,385. This change might impact tax liabilities.
• Added details on impairment loss resulting in a write-down of assets, excluding financial assets, with a projected indefinite benefit. This may impact financial statements significantly.
• Topic 944 - SubTopic 220 changed from 740 to 235. This change may impact financial reporting significantly.
• Addition of new references related to Accounting Standards Codification sections indicates increased focus on compliance and reporting accuracy.
• Share price increased from $5.27 to $100. This significant change may impact investor sentiment.
• The Company received approval to sell $1.3 million of New Jersey net operating losses, increasing from $1.4 million in 2021.
• Operating loss carryforwards decreased from $30,030,000 to $21,430,000. This may affect future tax benefits.
• Stock options and restricted stock awards compensation decreased from $2.4 million to $0.6 million.
• Topic 924 - SubTopic 10 - Section S99 - Paragraph 1 was changed to Topic 924 - SubTopic 10 - Section 50 - Paragraph 4.
• Non-vested stock awards granted decreased from 69,650 to 22,100, a notable drop.
• Weighted average grant date fair value for non-vested stock awards decreased from $1.92 to $1.
• Accumulated other comprehensive income increased by $60 million to $796 million.
• Cash and cash equivalents decreased to $15 million in 2023 from $32 million in 2022.
• Changes in the fair values of financial instruments, with Corporate debt securities and U.S. treasury obligations showing significant fluctuations.
• Common stock outstanding decreased from 6,600,000 to 400,000 shares. This change affects ownership distribution.
• The Earn-out Milestone Liability increased from $7.0 million in 2021 to $5.4 million in 2023.
• Topic 835 - SubTopic 20 - Section 50 - Paragraph 1 changed from 10 to 55. This change may affect accounting practices.
• Issued 1,653,878 shares of common stock in 2023, raising $2.8 million in net proceeds.
• Treasury stock shares decreased from 5,770,538 to 5,770,516, a minor reduction.
• Enhanced information on Stock Issued During Period Shares, including Restricted Stock Awards.
• Impairment charge on reclassified assets increased by $13,366,234 from the previous period.
• The Company received approximately $1.3 million upon completion of the sale of the 2023 NOLs.
• Stock-based compensation increased from $2,673,034 to $3,759,737.
• Cash and cash equivalents decreased from $32 million to $15 million in 2023.
• The company's ability to raise capital may impact its ability to continue as a going concern.
• Increased loss from operations from $21,030,430 to $25,421,565, impacting profitability and financial health.
• The number of shares outstanding increased from 9,399,789 to 9,089,399, impacting ownership dilution.
• The Company sold the 2023 NOLs for approximately $1.3 million, similar to the proceeds received in 2022.
• Addition of new accounting standards codification topics 210, 360, and 944 with specific details.
• Named Executive Officer compensation details added for 2023, e.g., Corinne Le Goff's total compensation increased to $1,055,814.
• Addition of new references and details in various sections of the Accounting Standards Codification.
• The company received approximately $1.3 million upon completion of the sale of the 2023 NOLs.
• The early termination fee decreased from $150,000 to $120,000, impacting the total payoff amount.
• Topic 326 - SubTopic 20 now includes Section 50 - Paragraph 3A, a notable change.
• Deferred tax assets decreased from $79,915,000 to $67,800,000 as of December 31, 2023.
• Lessee's undiscounted obligation for lease payment now includes the second fiscal year.
• Reduced R&D expenses by $1.4 million in 2023, with significant decreases in various study costs.
• Topic 220 - SubTopic 10 - Section S99 - Paragraph 2 changed from 50 to 22. This change may impact financial disclosures.
• Restricted cash reduced to $3 million in 2023 from $6 million in 2022.
• Net operating losses reduced from $79,915,800 to $67,310,000. This could impact tax planning.
• The FASB issued ASU No. 2023-09, impacting income tax disclosures and financial instruments.
• The Company's diluted loss per common share increased from 988,389 shares in 2022 to 1,255,642 shares in 2023.
• Total stockholders' equity decreased by $15 million to $13,387,642 million.
• Topic 985 - SubTopic 20 - Section 50 - Paragraph 1 was changed to Topic 985 - SubTopic 20 - Section 25.
• The Company adopted ASU No. 2016-13 in the first quarter of 2021, impacting income tax disclosures.
• Topic 740 - SubTopic 10 saw the addition of Section 45 - Paragraph 6, a material update.
• Number of warrants issued decreased from 175,792 to 168,519 in 2023.
• Introduction of new subtopics and sections within the accounting standards codification for better categorization.
• Inclusion of specific references and details regarding Stock Issued During Period Shares.
• Stock option grants for Non-Employee Directors in 2023 were disclosed, e.g., James E. Dentzer received 2,000 options.
• Operating lease liability payments due increased from the fourth to the third fiscal year.
• Deferred income tax asset increased from $286 to $641.
• Notable adjustments in the Property, Plant, and Equipment section, particularly in the values of Machinery and equipment and Leasehold improvements.
• Preferred stock value changed from $0.219 to $0.197 per share, impacting equity.
• Warrants issued decreased from 2,500,000 to 200,000. This change impacts potential future dilution.
• End-of-term charges increased from $275,000 to $300,000, affecting the total payoff amount.
• Operating lease payments decreased from $646,633 to $644,593, affecting cash flow management.
• Non-vested restricted stock awards outstanding decreased from 1,481 to 1,464 as of December 31, 2023.
• Accumulated depreciation, depletion, and amortization for property, plant, and equipment decreased by $541,605.
• Warrants outstanding and exercisable decreased from 175,792 to 160,060 at December 31, 2023.
• Earn-out milestone liability written off, resulting in a non-cash gain of $5.4 million in 2022.
• Loss on debt extinguishment changed from $234 to $329, affecting financial position and debt management.
• Changes in balance values from 2022 to 2023, e.g., TotalBeginning balance, value: $27 million to $74 million.
• The Company recognized a non-cash loss of $622,000 in the Earn-out Milestone Liability balance for 2022.
• Options outstanding decreased from 760 to 1,063 shares, while exercisable options decreased from 201 to 453 shares.
• Director Compensation table added, e.g., James E. Dentzer earned $61,195 in total in 2023.
• Addition of new details related to Net Income Loss and Other Comprehensive Income Loss.
• Loss on extinguishment of debt decreased from $329,158 to $0.
• Weighted average exercise price of stock options outstanding decreased from $3.64 to $3.27.
• The FASB issued ASU No. 2021-09, affecting earnings per share, effective for fiscal years starting after December 15, 2021.
• Topic 210 - SubTopic 10 now includes Section S99 - Paragraph 1 - Subparagraph (SX 210. 5 - 02 (17)), a notable change.
• Maximum annual retirement contributions increased from $107,000 to $142,000.
• The company renewed its office lease agreements, with monthly rent payments changing from $22,983 to $23,394.
• Increase in shares from 2,713,402 to 7,436,219 at Dec. 31, 2022, and from 2,713,402 to 7,436,219 at Dec. 31, 2023.
• General and administrative expenses decreased by $3.9 million in 2023 due to lower costs.
• The number of Warrants outstanding decreased from 168,519 in 2022 to 160,060 in 2023.
• General and administrative expenses rose from $9,742,739 to $13,687,899, impacting operational costs.
• Operating losses expected to fluctuate significantly in the future, impacting profitability outlook.
• Impairment of goodwill and in-process research and development decreased from $13,366,234 to $1,976,101.
• Discretionary retirement contributions increased from $172,000 to $233,000.
• Stock Ownership Guidelines for Directors introduced, requiring a stake equal to 2x total compensation.
• The company sold New Jersey NOLs, receiving net proceeds of $1.3 million in 2023, down from $1.6 million in 2022.
• Recognized $1.3 million in tax benefits from the sale of New Jersey NOLs in Q4 2023.
• The Company modified its stock-based compensation plan in December 2023.
• The Company's discretionary contribution to the Retirement Benefits plan decreased from $142,000 in 2021 to $117,000 in 2023.
• Research and development expenses increased from $11,287,691 to $11,733,666, affecting innovation and product development.
• Capital requirements emphasized with essential expenditures for drug candidates and technologies.
• Topic 852 - SubTopic 10 added Section 50 - Paragraph 7 - Subparagraph (b), a significant addition.
• Details on the Convertible Note Purchase Agreement with Transomic Technologies, Inc. in 2022.
• The Company's net loss decreased from $35.9 million in 2022 to $19.5 million in 2023.
• The company entered into a $100 million loan facility with Silicon Valley Bank, repaid in full in June 2023.
• Topic 852 - SubTopic 10 now includes Section 50 - Paragraph 7 - Subparagraph (b), a material change.
• Total lease liabilities increased from $238 million in 2022 to $626 million in 2023.
• Amortization of deferred finance charges and debt discount associated with note payable increased from $55,122 to $181,259.
• Net cash used in operating activities decreased to $19 million in 2023 from $23 million in 2022.
• Stock options outstanding increased from 441,425 in 2021 to 1,063,482 in 2023.
• Management's assessment of going concern basis detailed, highlighting uncertainties in research and development projects.
• Net loss per common share increased from $2.16 to $5.03, impacting shareholder value and investor perception.
• Operating lease liabilities increased from $714 million to $1.624 billion in 2023.
• The Company's total assets decreased from $43.98 million in 2022 to $21.92 million in 2023.
• Director Independence disclosure provided, with five independent directors identified under SEC and Nasdaq rules.
• Accounts payable and trade increased from $302,404 to $1,039,372.
• Investment income increased to $1.2 million in 2023 from $0.5 million in 2022.